Analysts are now focused on the when the change will actually happen, as the cannabis industry waits for tax relief and expanded research opportunities. ...

Tilray Brands, Inc. (NASDAQ:TLRY) is one of the stocks Jim Cramer was asked about. When a caller asked about the stock during the lightning round, Cramer stated: “It’s a kaching kaching. I want you to sell half, and if they approve it, then you sell the other half. You see, because what they lack is earnings.” Copyright: atomazul / 123RF Stock Photo Tilray Brands, Inc. (NASDAQ:TLRY) produces and sells medical and adult-use cannabis, beverages, hemp-based foods, and wellness products. On December 11, t ...

NEW YORK, NY / ACCESS Newswire / December 19, 2025 / Cannabis did not design its infrastructure for permanence. It designed it for speed. ...

Key Points Tilray Brands' stock performance hinges on the outlook for marijuana reform in the U.S. President Trump is considering rescheduling marijuana, which has investors bullish on Tilray of late. The company's financial results, however, show that marijuana revenue declined in its most recent fiscal year. 10 stocks we like better than Tilray Brands › Tilray Brands (NASDAQ: TLRY) can be a polarizing stock to own. While on the one hand, investors are optimistic about the potential for it to ta ...

Core Insights - Tilray Brands is a global leader in the medical cannabis industry, facing competition from major companies like Canopy Growth and Cronos Group [1] Summary by Sections Stock Performance - Bernstein maintained a "Market Perform" rating for Tilray, raising the price target from $1 to $10, while the stock was priced at $12.34 [2] - Despite the hold recommendation, Tilray's stock decreased by 4.2%, closing at $12.34, with trading volume surging to 66.7 million shares, a 514% increase from the three-month average of 10.9 million shares [3][6] - The stock fluctuated between $12.10 and $15.69 during the day, with a market capitalization of approximately $1.38 billion [5] Market Context - The broader market saw gains, with the S&P 500 rising by 0.79% and the Nasdaq Composite increasing by 1.38%, but not all cannabis stocks benefited, indicating market anticipation of the policy change [4][6] - Prior to the executive order reclassifying marijuana, Tilray's stock had surged over 50% due to rumors, which were confirmed by the order [4]

Key Points Investors felt the cannabis executive order didn't go far enough. Tilray's CEO backed President Trump's decision, but called it an "incremental step." 10 stocks we like better than Tilray Brands › It was an exciting week in the cannabis sector. Rumors that President Trump was planning to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA) had pot stock shares soaring. The stock of global cannabis company Tilray Brands (NASDAQ: TLRY) was up 28% ...

Our Brandon Gomez has more on why that move came about and why now. Hey Brandon, >> instead investors clearly seeing more haze ahead. Still, the group holding solid gains monthto date.Let's start with what actually happened yesterday. President Trump signed an executive order directing the DEA to reclassify cannabis from schedule 1 to schedule 3. Now that eases restrictions on medical research, banking, and taxes.The administration also launched a Medicare pilot program allowing some seniors starting in Apr ...

Tilray ( TLRY ) announced its entry into US cannabis markets today as Trump signed an EO to reschedule cannabis. The Executive Order directs the federal government to finish the process of reschedulingWelcome to the home of The Cannabis Report. I cover the cannabis sector and other sectors. I am most interested in technical stock analysis, option strategies, small cap strategies, and emerging markets. Feel free to contact me with any questions about publicly traded stocks in the cannabis industry.Analyst’s ...

Trump just made the biggest federal cannabis move in over 50 years, and Wall Street is already reacting. I'm Bernie Gomez at CNBC headquarters, and President Trump has officially signed an executive order reclassifying cannabis, moving it out of schedule one, the same category as heroin, and into schedule 3. That change eases restrictions on research, banking, and taxes, and could reshape the entire cannabis industry.Now, Trump says the move is about patients, including veterans, seniors, and people with ch ...

Core Insights - The cannabis industry is transitioning towards a phase where identity is becoming more significant than narrative as federal oversight begins to take shape [1] - The industry is moving away from a fragmented state system towards a more unified regulatory framework that resembles other regulated categories [1] Industry Overview - Federal oversight is expected to streamline the cannabis industry, reducing the complexity of the current patchwork of state regulations [1] - This shift may lead to increased legitimacy and stability within the cannabis market as it aligns more closely with established regulatory frameworks [1]